Breast Density Legislation and Clinical Evidence
Breast Density Legislation and Clinical Evidence
复制标题
DOI：
10.1016/j.rcl.2016.12.006
复制
发表时间：
2017-05-01
影响因子：
1.9
通讯作者：
Hooley, Regina J.
中科院分区：
文献类型：
--
作者：
Hooley, Regina J.
乳腺密度告知立法在美国被广泛接受，并推动了关于乳腺X线摄影中致密乳腺组织的临床意义和补充筛查价值的研究。本文综述了乳腺密度的起源和现状，为乳腺密度的最佳测定提供了依据和策略。致密乳腺组织与乳腺癌风险增加相关的临床证据，以及与其他风险因素相比的相对风险的审查。最后，对补充筛查方式（包括超声、断层合成和MRI）的原理、受益和风险进行了深入分析。
Breast density inform legislation is widely accepted in the United States and has fueled research regarding the clinical significance of dense breast tissue present on mammography and the value of supplemental screening. This article reviews the origins and current status of breast density inform laws and strategies for optimal breast density determination. Clinical evidence that dense breast tissue is associated with increased breast cancer risk is presented, together with a review of relative risk compared with other risk factors. Finally, there is in-depth analysis regarding the rationale, benefits, and risks of supplemental screening modalities, including ultrasound, tomosynthesis, and MRI.